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Abstract: The history of hormone replacement therapy (HRT) started in the 1960s, with very high
popularity in the 1990s. The first clinical trials on HRT and chronic postmenopausal conditions were
started in the USA in the late 1990s. After the announcement of the first results of the Women’s
Health Initiative (WHI) in 2002, which showed that HRT had more detrimental than beneficial effects,
HRT use dropped. The negative results of the study received wide publicity, creating panic among
some users and new guidance for doctors on prescribing HRT. The clear message from the media
was that HRT had more risks than benefits for all women. In the following years, a reanalysis of the
WHI trial was performed, and new studies showed that the use of HRT in younger women or in
early postmenopausal women had a beneficial effect on the cardiovascular system, reducing coronary
disease and all-cause mortality. Notwithstanding this, the public opinion on HRT has not changed
yet, leading to important negative consequences for women’s health and quality of life.
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1. From the Past to the Present
In the 20th century, the interest in menopausal disorder has been increasing, but it took a long time
to realize the real impact of hormone depletion on women’s health. The clinical conditions associated
with menopause were identified as “Hormone Deficiency Syndrome” [1], which included, besides
hot flashes, other late onset chronic diseases such as osteoporosis, cardiovascular events, Alzheimer’s
disease, and vaginal atrophy. At the beginning of the 20th century, the Food and Drug Administration
(FDA )approved an estrogen product for the first time, Preamirin®, for the treatment of hot flashes [2].
The feminist movement in the 1960s changed women’s status and life expectancy, encouraging
menopausal therapy, especially in European countries, with the concept of “feminine forever”. Wilson’s
book, published in 1966 (“feminine forever”), became a bestseller, with its claim that “menopause
is a hormone deficiency disease, curable and totally preventable, just take estrogen” [3]. Hormone
replacement therapy (HRT) was presented as a therapy that could allow women to free themselves
from the malediction of estrogen loss and conserve their femininity. In the 1970s, the finding that
unopposed estrogen supplements were associated with an increased risk of endometrial cancer had
a bad impact on HRT’s reputation [4,5]. Ziel et al. observed a probable connection between the
administration of conjugated estrogen alone and the development of endometrial cancer [4].
Nevertheless, in the following years, researchers discovered that reducing the dosage of estrogen
and combining it with progesterone could reduce the risk of endometrial cancer [6]. Such combined
therapy was recommended for women with an intact uterus, raising renewed enthusiasm for
HRT treatment.
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The FDA initially approved HRT only for the treatment of hot flashes and not for the prevention of
chronic conditions, but in 1988 the prevention of osteoporosis was included among the FDA-approved
indications [7,8].
Furthermore, in the same years, numerous observational studies [9–12] suggested that HRT
had various benefits, not only with regard to the treatment of menopausal symptoms, but also in
the prevention of chronic diseases. Thus, the idea switched from “feminine forever” to “healthy
forever”. The use of HRT increased further, and the American College of Physicians developed the
first guidelines for using HRT as a preventative therapy for the chronic diseases of postmenopausal
women [13,14], even if experts raised some concern about the impact that progestin may have on
estrogen benefits, particularly in the cardiovascular system [15].
On the basis of the claimed positive effect of HRT on cardiovascular health, the FDA required that
this supposed HRT-induced cardiovascular benefit be confirmed by randomized clinical trials.
The first randomized clinical trial was a study of secondary prevention of cardiovascular
disease, the Heart and Estrogen/Progestin Replacement Study (HERS) [16]. This study enrolled 2736
postmenopausal women with established coronary heart disease. Enrolled women were randomized
to receive HRT (0.625 mg of conjugated equine estrogens and 2.5 mg of medroxyprogesterone acetate)
or a placebo. No difference was found between the two groups after four years of follow-up, but in the
HRT group, an increase of coronary events (nonfatal myocardial infarction or coronary heart disease
(CHD) death) was found after one year. This induced increase declined in the subsequent years [16].
In 1998, the Women’s Health Initiative (WHI) was started, which was the largest randomized
study to date that was aimed at evaluating the effect of HRT on the most common causes of death
and disability in postmenopausal women, such as cardiovascular disease, cancer, and osteoporosis.
Women with uteri (16,608 participants) were randomized and received a combination of 0.625 mg
Conjugated Equine Estrogens (CEE) and 2.5 mg of medroxyprogesterone acetate, and women without
uteri (10,739 participants) were randomized and received 0.625 mg of conjugated equine estrogen
or a placebo. The first results of the WHI were published in 2002 after a mean follow-up period
of 5.2 years. In the group with intact uteri, an increased incidence of coronary heart disease and
breast cancer was observed in concomitance with a reduction of osteoporotic fractures and colorectal
cancer [17]. Given these results, it seemed that the risks outweighed the benefits, and the trial was
prematurely discontinued. The data were largely disseminated to the media, creating panic among
HRT users and forcing new guidance for doctors on prescribing HRT. The message was that HRT,
with no specification of type and route of administration, was associated with more risks than benefits.
However, no distinction was made between users and their age.
The trial with only estrogen (performed in hysterectomized women) continued, and the preliminary
data were published in 2004 [18]. In addition, this trial was stopped prematurely after 6.8 years of
follow-up due to evidence of a small increased risk of ischemic stroke in the absence of other significant
cardiovascular benefits [18]. In spite of the benefits (such as a reduction of osteoporotic fracture and
colon cancer) and of the not-increased risk of breast cancer or cardiovascular disease, the overall
message on HRT remained negative. After these announcements, the UK regulatory authorities
issued an urgent safety restriction about HRT, recommending that doctors should prescribe the lowest
effective dose for symptom relief, should use it only as a second-line treatment for the prevention of
osteoporosis, and should not use it in asymptomatic postmenopausal women.
Since that time, there have been ongoing discussions and controversies about the WHI design and
conclusions, and many of its results have been extensively debated. It emerged that one important
limitation of the WHI was that most of the participants were more than a decade past their final
menstrual period, raising the question of whether the results of the trial could be applied to younger
women. Furthermore, the WHI tested only CEE either alone or in combination with a single progestin,
medroxyprogesterone acetate. As a result, the WHI findings did not answer doubts about the safety
and effectiveness of other HRT formulations, regimens, and delivery methods. Despite its limitations,
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the WHI had a negative impact on the global perception of HRT, leading to a marked decline in HRT
utilization. Many doctors stopped prescribing HRT, and many women abandoned HRT immediately.
It has been suggested that the conflicting findings between the WHI and previous observational
studies were the consequence of the different ages of the enrolled women. Some observational studies
had included symptomatic women who had started HRT near the onset of menopause, while women
enrolled in the WHI trial were asymptomatic, older (average age 63.2), and frequently more than
10 years on from the start of menopause. It has been suggested that a “window of opportunity” may
exist, a period of time close to menopause where the benefits of HRT exceed the risks [19].
The follow-up of the WHI continued for 13 years, and some results, including an age stratification
of the cardiovascular outcomes, were published in the following years [20–23]. A reanalysis of the WHI
trial with new studies and a metanalysis showed that the use of HRT in younger women (50–59 years)
or in early postmenopausal women (within 10 years of menopausal onset) had a beneficial effect on the
cardiovascular system, reducing coronary diseases and all-cause mortality [22,24–27]. Furthermore,
a large controlled trial from Denmark (reported in 2012) demonstrated that healthy women taking
combined HRT for 10 years immediately after menopause had a reduced risk of heart disease and
death from heart disease [28]. Unfortunately, these data did not receive appropriate coverage by the
media, and the fear regarding HRT has persisted.
Thus, the story of HRT over the years has shown a trend with two peaks of utilization: a first rise
in the 1960s and a second, higher increase in the years 1999–2000, before the publication of the WHI
data. After these years, there was a precipitous decline in HRT use in many countries [29]. For instance,
the use of HRT dramatically declined by 46% in the USA [30] and by 28% in Canada [31], and similar
data were observed in European countries such as Germany [32,33] or the United Kingdom [34].
If HRT was really harmful to the health of postmenopausal women, its massive reduction in use
should have resulted in an improvement in women’s health. Observational studies have tried to show
trends of hormone-related cancers and chronic conditions following the WHI publications. Cancer and
chronic conditions are multifactorial, and modification of a single factor, such as HRT use, may not
result in a clear epidemiological change. Still, the analysis of epidemiological trends or modifications in
the post-WHI era may give additional insights into the role played by HRT in women’s health (Table 1).
Table 1. Epidemiological modification in the incidence of hormone-related cancers, cardiovascular
disease (CVD), and bone fractures in the post-Women’s Health Initiative (WHI) era.
Disease Modification
Breast Cancer Decreased or Unchanged
Endometrial Cancer Increased
CVD Increased or Unchanged
Bone Fractures Increased or Unchanged
In bold is the stronger evidence.
2. Breast Cancer
2.1. Effect of HRT
Over the years, data regarding the impact of HRT on breast safety and breast cancer mortality have
been controversial. Most of the meta-analyses and observational studies performed in the 1990s reported
no increase in the risk of breast cancer with estrogen use [35]. However, some increased risks related
to dose and duration of use were found with the administration of combined estrogen–progesterone
therapies [36].
The WHI reported an increased risk of breast cancer in the women treated with a combination of
conjugated estrogen and medroxyprogesterone acetate [17], a risk that was significantly higher than in
placebo users after 5.6 years of treatment (approximately 6–7 years) [37,38]. Vice versa, the risk of breast
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cancer was significantly lower than in placebo users for those women treated with only conjugated
estrogen [37,39]. One important, but incorrect, thought reported by the media after the WHI trial
publication was that HRT causes breast cancer “de novo”. However, this study did not distinguish
between de novo tumor development and the growth of an occult tumor present before the beginning
of therapy. After analyses of the biology of occult tumors, current opinion about breast safety with HRT
has changed. The modern thinking is that estrogen could have a promotional and noncarcinogenic
effect on occult tumor cells and that this effect is probably greater with an estrogen–progesterone
therapy [40].
2.2. Consequence of HRT Withdrawal
Following the publication of the WHI results and the associated drop of HRT use, some envisioned
a concomitant decline of breast cancer incidence. However, the impact of HRT cessation showed an
important variability between nations. Clarke and colleagues were the first to publish data about
the incidence of breast cancer between 2001 and 2003 [41]. The authors reported that after the WHI
publication, the use of HRT in northern California declined by 68%, and at the same time, breast cancer
incidence declined by 10%. A study performed in California between 2001 and 2004 [42] similarly
hypothesized that a decline in breast cancer incidence was linked to reduced HRT use. These data
were in accordance with those observed in the Surveillance, Epidemiology, and End Results (SEER)
study, which showed a 6.7% decrease in breast cancer incidence in 2003 [29]. Other western countries
documented a reduction in breast cancer incidence after the reduced use of HRT [43]. In Germany,
breast cancer incidence declined by 8.8% annually from 2002 to 2005, with an almost 50% reduction in
HRT use [44]. In France, the breast cancer rate decreased by 14.7% from 2003 to 2007, with a reduction
in HRT use from 32% to 11% between the years 2001 and 2007 [45]. In Australia, a 6.7% decline in
breast cancer incidence was observed in 2003, with a simultaneous 8% reduction in HRT use between
2001 and 2003 [46]. In Canada, an 8% decreased incidence in breast cancer was observed every year
from 2002 to 2004, with a 15% reduction in HRT use [47].
In Italy, the Netherlands, and Spain, the absolute decline of therapy after 2002 did not translate
into a decline in breast cancer rates [43]. In addition, in the UK, the use of HRT showed a peak of 25%
in 2000 and decreased thereafter. In spite of that, breast cancer incidence declined 0.8% per year from
1999 to 2006 [48]. Interestingly, the incidence of estrogen receptor-positive breast cancer in the USA
increased to a maximum in 1999, with a downward trend starting in 2000, at least two years prior
to the WHI publications [43,49]. Moreover, after some years, there was a new rise in breast cancer
incidence (for both lobular and ductal breast cancer), such that by 2012, the rates were like those of
2001. This could mean that other factors besides HRT can explain the trend in breast cancer. Likely,
some of these data can be explained by changes in the national screening programs for breast cancer.
High rates of mammography, which has been extended to younger women, may have resulted in
a greater incidence of breast cancer in the years following screening implementation, followed by a
decline of breast cancer incidence as a consequence of the early diagnoses of the previous years [50,51].
3. Endometrial Cancer
3.1. Effect of HRT
The use of unopposed estrogen has been associated with an increased risk of endometrial
cancer [4]. Consequently, guidelines have indicated that in women with uteri, estrogen therapy should
be prescribed together with a progestin molecule [8]. Evidence of reduced endometrial cancer risk with
combined HRT was well represented in the HERS trial, which showed seven fewer endometrial cancer
cases per 10,000 in women using HRT than in placebo users [52]. Similarly, the Million Women Study
reported that combined HRT therapy reduced the risk of endometrial cancer [53]. Continuous combined
therapy has better endometrial safety than sequential therapy does [54,55]. A large Finnish case–control
study [56] showed that sequential therapy induced an elevated risk of endometrial cancer when used
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for longer than 10 years. However, the roles of different types of progestagen remain to be assessed.
In two observational studies, the most commonly used progestin molecules, norethisterone acetate and
medroxyprogesterone acetate, did not differ in their protection from endometrial cancer [53,56]. On the
basis of the literature, oral micronized progesterone administered sequentially for 12–14 days/month at
a dose of 200 mg/day is effective for endometrial protection for up to five years of use [57]. However,
for treatments longer than five years in the E3N cohort study [58], combined therapy with oral
micronized progesterone or dydrogesterone was associated with an increased risk of endometrial
cancer [59].
3.2. Consequences of HRT Withdrawal
After the WHI publication and the drop in HRT prescription, endometrial carcinoma rates
increased between 2001 and 2012 [60]. Similarly, in England, Martin and colleagues observed a change
in endometrial cancer mortality after 2002, with nine additional endometrial cancer deaths per year [51].
4. Cardiovascular Disease
4.1. Effect of HRT
The incidence of cardiovascular events increases in postmenopausal women, particularly in
those experiencing severe vasomotor symptoms. The Study of Women’s Health Across the Nation
(SWAN) showed that women with hot flashes had higher subclinical CVD, including greater aortic
calcification, poorer endothelial function, and higher intima media thickness, than did women without
menopausal symptoms [61–63]. Clinical studies have shown that HRT favorably impacts the risk
factors for CVD [64–69]. The clinical efficacy could be related to early treatment, but also could be
related to the administration of HRT to those with a higher cardiovascular risk due to their symptoms.
This was not the case in the WHI, where HRT was given years after menopause and to asymptomatic
women. Thus, it is not surprising that the results of the WHI trial did not confirm a protective effect of
HRT against coronary heart disease, stroke, and venous thromboembolism [17]. However, a reanalysis
of the data using age stratification reported that in women within 10 years of the onset of menopause,
the administration of HRT decreased the rate of coronary artery disease and all-cause mortality [22].
Two subsequent meta-analyses, which used cumulated data from 23 and 30 randomized clinical trials,
respectively, reported a decrease in CVD and all-cause mortality in HRT users younger than 60 years of
age or in those who began menopause less than 10 years prior [24,25]. More recent randomized trials
have tested the timing hypothesis, the Early versus Late Intervention with Estradiol (ELITE) study [70]
and the Kronos Early Estrogen Prevention Study (KEEPS) [71], and have reported a protective effect of
HRT in young women close to menopause. More recently, the Danish Osteoporosis Prevention Study
(DOPS) reported the same findings after 10 years of treatment with HRT versus a placebo [28].
4.2. Consequences of HRT Withdrawal
From the above data, it could be expected that a lack of treatment of symptomatic postmenopausal
women may have translated into an increase in cardiovascular events after 2002. A Finnish study
reported increased deaths from myocardial infarctions and strokes in women discontinuing HRT,
especially in those younger than 60 years of age [72]. In the USA, a report comparing male and female
mortality between two periods, the mid-1990s and between 2002 and 2006 [73], reported a reduction
in male mortality but an increase in female mortality in the same timeframe. An English ecological
study reported unfavorable changes in myocardial infarctions and strokes subsequent to the HRT
fall following the WHI publication [51]. In contrast, one ecological study performed in the USA after
2002 reported a correlation between the fall in HRT use and a reduced incidence of acute myocardial
infarction [74].
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5. Fractures
5.1. Effect of HRT
Postmenopausal osteoporosis is a consequence of estrogen withdrawal in which inflammation
plays a multifactorial role [75,76]. Clinical studies have unanimously shown that any kind of HRT is
capable of reducing bone turnover, reducing bone reabsorption, and increasing bone mineral density.
Both high bone turnover and low bone mineral density are risk factors for bone fractures. The supposed
preventive effect of HRT on bone fractures has been reported by many observational studies [77,78].
The WHI was the first randomized trial that showed the clear efficacy of HRT in reducing vertebral and
hip fractures by about 34% [17]. The same data were obtained in the DOPS study [79]. The effect was
demonstrated in a population of normal women that was not specifically suffering from osteoporosis,
i.e., a clinical situation where other antiosteoporotic therapies failed to show a preventive effect.
5.2. Consequences of HRT Withdrawal
The follow-up to the WHI study showed no increase in fractures five years after HRT
withdrawal [80]. In another observational study (after 15 years of follow-up), conserved beneficial
effects on bone were reported in women who used HRT for more than five years [81]. However, in a
large study, Islam and colleagues found that the risk of fractures in postmenopausal women increased
in the three years following the publication of the WHI [82]. An Italian analysis estimated 43,000 extra
bone fractures per year in the USA that were associated with decreased HRT use [83]. A more recent
longitudinal observational study concluded that women who discontinued HRT had a higher risk
of fractures compared to those who continued therapy, which has an important effect on women’s
health [84].
6. Conclusions
The controversial history of HRT is about the history of a powerful pathogenetic therapy for
all postmenopausal disturbances. Its effects on symptoms are and were immediately visible, at first
prompting rapidly growing estrogen use. A lack of knowledge about its side effects and complications,
particularly in the endometrium, prompted consequences that limited HRT use. Subsequent association
with progestin allowed for the widespread use of HRT, with favorable consequences on many aspects of
women’s health. Unfortunately, the surge in HRT use and its consolidation was abruptly stopped by the
publication of the WHI trial, which was inadequately designed, evaluated, and reported. The damage
done was huge, basically leaving many symptomatic women without an effective treatment, even if
the epidemiological data were not strong enough to document a clear harm to women’s health.
Although most of the evidence obtained was only with oral conjugated estrogen with or without
medroxyprogesterone acetate, further studies and analyses have consolidated the view that HRT is
highly beneficial when given to symptomatic women within 10 years since the onset of menopause or
to symptomatic women that are under 60 years of age. However, the damage remains, and low HRT
use, which is unjustified, continues to occur throughout the world.
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